Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,411 total articles

Eldorado Gold Provides Q1 2026 Conference Call Details

Eldorado Gold Provides Q1 2026 Conference Call Details

Eldorado Gold Corporation will release its financial and operational results for the first quarter of 2026 on April 30, 2026, and will host a conference call on May 1, 2026. The company operates gold and base metals mining and exploration projects in Canada, Türkiye, and Greece, and its shares trade on both the TSX and NYSE American exchanges.

Caliber and PURE Pickleball & Padel Announce Building Permit Approval for World’s Largest Indoor Pickleball and Padel Facility

Caliber and PURE Pickleball & Padel Announce Building Permit Approval for World’s Largest Indoor Pickleball and Padel Facility

Caliber (Nasdaq: CWD), a US-based diversified real estate and digital asset management platform, announced that PURE Pickleball & Padel's 196,000-square-foot indoor sports facility in Scottsdale, Arizona, has received all required building permits. This milestone paves the way for groundbreaking, expected after construction financing closes. The fa…

Calavo Growers Declares Quarterly Dividend

Calavo Growers Declares Quarterly Dividend

Calavo Growers, Inc., a leader in fresh produce sourcing and processing, declared a quarterly cash dividend of $0.20 per share. The company amended the dividend record date to April 24, 2026, while maintaining the payment date of April 29, 2026. This adjustment complies with Nasdaq's notice requirements without changing dividend value or payment ti…

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

Allogene Therapeutics announced encouraging interim futility analysis results from its Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel), an allogeneic CAR T therapy, in first-line consolidation for large B-cell lymphoma (LBCL). The cema-cel arm showed a 58.3% minimal residual disease (MRD) clearance rate versus 16.7% in the ob…

BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners

BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners

BullFrog AI Holdings announced a significant commercial feasibility agreement with a top 5 global pharmaceutical company to use its AI platform bfLEAP® to identify novel drug targets in major depressive disorder. The company also strengthened its balance sheet with recent financings to support operations into late 2027 and is advancing multiple dis…

ASP Isotopes Inc. Provides Business Update

ASP Isotopes Inc. Provides Business Update

ASP Isotopes Inc. presents a comprehensive business update highlighting operational milestones across its nuclear medicine, electronics, and nuclear energy platforms. The company anticipates first commercial shipments of several enriched isotopes including Silicon-28, Carbon-14, and Ytterbium-176 in 2026, expects to reach helium production capacity…

Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors

Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors

Palvella Therapeutics, a clinical-stage biopharmaceutical company specializing in rare skin diseases and vascular malformations, announced the appointment of John D. Doux, M.D., M.B.A., a recognized dermatologist and investor in rare skin disease therapies, to its Board of Directors. Dr. Doux's deep medical experience and previous advocacy for inno…

NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences

NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences

PMGC Holdings Inc.'s subsidiary NorthStrive Biosciences announces the successful transfer of the EL-32 Working Cell Bank to a U.S.-based fermentation facility, initiating manufacturing optimization aimed at scalable and cost-effective production. EL-32 is an engineered probiotic therapeutic targeting muscle preservation by modulating myostatin and …

3D Systems Accelerates Production-Scale Additive Manufacturing with New High-Throughput Platform and Next-Generation Factory Software

3D Systems Accelerates Production-Scale Additive Manufacturing with New High-Throughput Platform and Next-Generation Factory Software

3D Systems has unveiled its next-generation SLA 825 Dual stereolithography system offering 22% larger build volume and up to 25% faster print speeds to enhance production throughput. Alongside, it launched AddiTrak™, an advanced on-premises factory software platform for real-time fleet monitoring and process control. These innovations aim to accele…

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer

Revolution Medicines announced positive topline results from the RASolute 302 Phase 3 clinical trial evaluating daraxonrasib, an oral targeted therapy, in previously treated metastatic pancreatic ductal adenocarcinoma patients. The trial met all primary and key secondary endpoints, showing a significant improvement in progression-free survival and …

CVRx Reports Preliminary First Quarter 2026 Financial Results

CVRx Reports Preliminary First Quarter 2026 Financial Results

CVRx, Inc. announced preliminary unaudited financial results for Q1 2026, reporting approximately 20% revenue growth year over year to $14.7-$14.8 million. The company noted improvements in Medicare Advantage prior authorization approval rates following implementation of Category I CPT codes, and activated the first site in the BENEFIT-HF clinical …

Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences

Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company specializing in local, controlled drug delivery using its Diffusphere™ technology, announced participation in upcoming investor conferences in New York and Toronto. The company is advancing clinical trials for its lead products, including EP-104GI for eosinophilic esophagitis and…

Elite Express Holding Inc. Reports First Quarter 2026 Results

Elite Express Holding Inc. Reports First Quarter 2026 Results

Elite Express Holding Inc. reported first quarter 2026 financial results showing a 16.3% year-over-year revenue increase to $805,298 and a 46.3% reduction in net loss to $110,104. Improvements were driven by increased delivery volumes, better route and fleet management, and labor efficiency. The renewal of its ISP agreement with FedEx contributed t…

VisionWave Acquires xClibre™ AI Video Intelligence IP Assets

VisionWave Acquires xClibre™ AI Video Intelligence IP Assets

VisionWave Holdings, a Nasdaq-listed defense technology company, has acquired the xClibre AI video intelligence intellectual property valued at approximately $60 million. The acquisition enhances VisionWave's sensing architecture by adding AI-driven video analytics to their existing RF-based detection systems. The company plans to integrate xClibre…